CAR-T cell therapy for B cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 6 months.
- Your lymphoma cells have specific markers (CD19, CD22, CD70, PSMA, CD13, CD79b, or GD2) that the therapy targets.
- You are generally in good health, with a performance score of 80 or above, and expected to live more than one month.
- Your hemoglobin level is above 80 g/L.
- You have no medical reasons that prevent collecting your blood cells.
- You do not have uncontrolled infections, HIV, active hepatitis B or C, and are not pregnant or nursing.
- You have not had CAR-T therapy before, and you are not currently on systemic steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
This trial is testing a special cell therapy that targets two markers on cancer cells to treat certain blood cancers. It may help people whose cancer has not gotten better with other treatments.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a new type of CAR-T therapy (a treatment that trains your immune cells to attack cancer) for people with certain types of B-cell leukemia that are CD19 negative or have relapsed after CD19 treatment. It may help if your cancer has other markers like CD22 or CD123.
This trial tests a type of immune therapy called CAR-T cells to treat autoimmune diseases. The treatment targets B cells, which are part of the immune system that can attack your own body in autoimmune conditions.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new B Cell Lymphoma (BCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.